Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ifosfamide
Drug ID BADD_D01133
Description Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
Indications and Usage Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.
Marketing Status Prescription; Discontinued
ATC Code L01AA06
DrugBank ID DB01181
KEGG ID D00343
MeSH ID D007069
PubChem ID 3690
TTD Drug ID D02TLO
NDC Product Code 10019-925; 63323-142; 15308-0411; 10019-929; 57884-0006; 0338-3991; 0143-9530; 10019-926; 0143-9531; 10019-927; 65124-0001; 0703-3427; 0338-3993; 0703-3429
Synonyms Ifosfamide | Isofosfamide | Isophosphamide | Iphosphamide | Iso-Endoxan | Iso Endoxan | Holoxan | NSC-109,724 | NSC 109,724 | NSC109,724 | NSC-109724 | NSC 109724 | NSC109724 | Asta Z 4942
Chemical Information
Molecular Formula C7H15Cl2N2O2P
CAS Registry Number 3778-73-2
SMILES C1CN(P(=O)(OC1)NCCCl)CCCl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
AminoaciduriaBeta-2-microglobulinP61769T580802386379; 8774570; 9261752; 1503924; 8625085; 9950195; 2060086; 1718222; 8318805; 10234592; 8070011; 10817497; 2510931; 8018491; 7787938; 8570867; 12868118; 12402147; 7510155
AnxietyAlpha-2A adrenergic receptorP08913T114487938249; 11425914
Arterial disorderElastinP15502Not Available2184650; 4077233; 10491730; 7033951; 3341387; 6489195; 2184657; 6394516; 6869203; 6616523; 9486085; 3277415; 11026649; 8562468; 6856486
Drug toleranceAlpha-2A adrenergic receptorP08913T114487938249; 11425914
GlycosuriaBeta-2-microglobulinP61769T580802386379; 8774570; 9261752; 1503924; 8625085; 9950195; 2060086; 1718222; 8318805; 10234592; 8070011; 10817497; 2510931; 8018491; 7787938; 8570867; 12868118; 12402147; 7510155
HypophosphataemiaBeta-2-microglobulinP61769T580802386379; 8774570; 9261752; 1503924; 8625085; 9950195; 2060086; 1718222; 8318805; 10234592; 8070011; 10817497; 2510931; 8018491; 7787938; 8570867; 12868118; 12402147; 7510155
Metabolic disorderS-adenosylmethionine decarboxylase proenzymeP17707T559226305362; 6121595; 6284819; 685624; 842265; 6617953; 204937
Metabolic disorderOrnithine decarboxylaseP11926T603666305362; 6121595; 6284819; 685624; 842265; 6617953; 204937
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Salivary hypersecretion07.06.01.009--Not Available
Sarcoma15.09.03.002; 16.33.01.002--Not Available
Second primary malignancy16.16.01.0140.000208%
Seizure17.12.03.0010.001066%
Sepsis11.01.11.0030.000139%
Septic shock24.06.02.011; 11.01.11.0040.000208%Not Available
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.003--Not Available
Skin hyperpigmentation23.05.01.003--
Skin necrosis23.03.03.011--Not Available
Somnolence17.02.04.006; 19.02.05.003--
Spermatogenesis abnormal21.03.03.002--Not Available
Status epilepticus17.12.03.0050.000799%Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.020--
Stomatitis07.05.06.005--
Stupor19.02.05.004; 17.02.04.007--Not Available
Supraventricular extrasystoles02.03.03.011--Not Available
Swelling08.01.03.015--Not Available
Swelling face23.04.01.018; 10.01.05.018--Not Available
Tachycardia02.03.02.0070.001598%Not Available
Tenderness08.01.08.005--Not Available
Thrombocytopenia01.08.01.0020.003463%Not Available
Thrombocytosis01.08.02.0010.000533%Not Available
Thrombophlebitis24.01.02.001--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 10.01.01.006; 11.07.01.006--
Tremor17.01.06.0020.000799%
Tumour lysis syndrome16.32.03.002; 14.05.01.004--
Unresponsive to stimuli17.02.05.0310.000533%Not Available
Urethral disorder20.07.01.002--Not Available
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 13 Pages